New Breast Cancer Drug Fails Cost-Effectiveness Tests in US and China
A new economic evaluation finds that datopotamab deruxtecan is not cost-effective compared with chemotherapy for advanced triple-negative breast cancer in ...
A new economic evaluation finds that datopotamab deruxtecan is not cost-effective compared with chemotherapy for advanced triple-negative breast cancer in ...
A comparative analysis of the phase III ASCENT-03 and TROPION-Breast02 trials demonstrates that first-line TROP2-targeting antibody–drug conjugates consistently improve progression-free ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.